Proteogenomics is an area of research at the interface of proteomics and genomics. In this approach, customized protein sequence databases generated using genomic and transcriptomic information are used to help identify novel peptides (not present in reference protein sequence databases) from mass spectrometry-based proteomic data; in turn, the proteomic data can be used to provide protein-level evidence of gene expression and to help refine gene models. In recent years, owing to the emergence of new sequencing technologies such as RNA-seq and dramatic improvements in the depth and throughput of mass spectrometry-based proteomics, the pace of proteogenomic research has greatly accelerated. Here I review the current state of proteogenomic methods and applications, including computational strategies for building and using customized protein sequence databases. I also draw attention to the challenge of false positive identifications in proteogenomics and provide guidelines for analyzing the data and reporting the results of proteogenomic studies.
Proteogenomics is an area of research at the interface of proteomics and genomics. In this approach, customized protein sequence databases generated using genomic and transcriptomic information are used to help identify novel peptides (not present in reference protein sequence databases) from mass spectrometry-based proteomic data; in turn, the proteomic data can be used to provide protein-level evidence of gene expression and to help refine gene models. In recent years, owing to the emergence of new sequencing technologies such as RNA-seq and dramatic improvements in the depth and throughput of mass spectrometry-based proteomics, the pace of proteogenomic research has greatly accelerated. Here I review the current state of proteogenomic methods and applications, including computational strategies for building and using customized protein sequence databases. I also draw attention to the challenge of false positive identifications in proteogenomics and provide guidelines for analyzing the data and reporting the results of proteogenomic studies.
Proteomics is the comprehensive, integrative study of proteins and their biological functions. The goal of proteomics is often to produce a complete and quantitative map of the proteome of a species, including defining protein cellular localization, reconstructing protein interaction networks and complexes, and delineating signaling pathways and regulatory post-translational protein modifications 1 .
Proteomic data are generally obtained using 'shotgun proteomics' , a combination of liquid chromatography (LC) and tandem mass spectrometry (MS/MS) 2 . A key step in proteomics is identifying peptides from acquired MS/MS spectra ( Fig. 1) . Unlike genomic technologies, in which the DNA or RNA fragments are actually sequenced, in proteomics, peptides are most commonly identified by matching MS/MS spectra against theoretical spectra of all candidate peptides represented in a reference protein sequence database 3 . The underlying assumptions are that (i) all protein-coding sequences in the genome are known and accurately annotated as a collection of gene models and (ii) all protein products of these gene models are present in a reference protein sequence database-such as Ensembl, RefSeq or UniProtKB-used for peptide identification (Box 1). Much of the subsequent data analysis and interpretation, including inference of the protein identity 4 and protein quantification using the sequences and abundances of the identified peptides, is based on these assumptions.
A problem with these assumptions is that many peptides are not present in a particular reference protein sequence database, or any reference database. Peptides may contain mutations and may represent novel proteincoding loci or alternative splice forms. One strategy to account for peptides with mutations is to use sequence tag-based database searching: several short peptide sequence tags are extracted from the spectrum, and the list of candidate peptides is restricted to only those peptides that contain one of the extracted sequence tags 5 . This allows for mutations in the sequences of candidate database peptides. Another strategy is to perform de novo sequencing 6 , but this approach is computationally inefficient and error prone for large-scale studies.
An alternative, more comprehensive approach to identify novel peptides is 'proteogenomics' . The term was first tome sequencing (RNA-seq) 8 data are now available in the public domain. More recently, RNA-seq technology has been extended to global analysis of translational products (ribosome profiling) 9 . These data suggest the presence of thousands of novel transcripts on top of the reference transcripts defined by the ongoing genome-annotation efforts such as RefSeq or GENCODE (Ensembl). Publicly available proteomic data may be mined to obtain protein-level evidence of expression of the novel transcripts nominated by genomic and transcriptomic technologies 10 . Furthermore, as generation of both transcriptomic and proteomic data in parallel is becoming increasingly common, there is an emerging trend of identifying peptides and proteins using proteomic data by matching MS/MS spectra against sample-specific protein sequence databases generated with the help of RNA-seq (and/or ribosomeprofiling data) from the same samples [11] [12] [13] [14] [15] [16] .
Proteogenomic approaches have been brought into the spotlight with recent largescale human proteome studies identifying large numbers of novel peptides and peptide variants [17] [18] [19] . At the same time, there is a growing concern that the scale of these studies challenges our ability to accurately process the data and to estimate false discovery rates (FDRs), especially for novel peptides. It is therefore an opportune time to review the current state of proteogenomics, including the computational strategies and error-rate estimation methods that are central to this area of research.
PROTEOGENOMIC TECHNOLOGY Type of peptides identified in proteogenomics
Different classes of peptides identified in proteogenomics map to different locations on the genome (Fig. 3) . Peptides can be classified as intergenic (mapping to regions located between annotated gene models) or intragenic (mapping to genomic regions contained within or in close proximity to an annotated gene model). Intragenic peptides can be further categorized on the basis of the annotation of the corresponding gene model (for example, "protein-coding gene, " "long noncoding RNA (lncRNA) gene" and "pseudogene" 20 when using Ensembl (GENCODE) as reference; see Box 1). The majority of peptides identified in proteogenomic studies (at least for commonly studied, well-annotated organisms) are known peptides that map to a protein-coding gene. In eukaryotes (with an intron-exon structure of genes), most of these peptides are localized within an exon, and the remaining peptides-typically less than 20%-span an exon-exon junction. Novel peptides not found in any reference protein database include those that identify previously undiscovered protein-coding loci (intergenic peptides) and variant peptides (for example, singleamino-acid variants, or SAVs). Depending on the organism, these may also include peptides mapping to untranslated regions (3ʹ or 5ʹ UTR) or introns, peptides spanning the boundary between the introduced in the literature in 2004 (ref. 7) and was initially used to describe studies in which proteomic data are used for improved genome annotation and characterization of the protein-coding potential. The term has since been broadened to include any type of application in which a proteogenomic-like approach is used to interpret MS/MS spectra. In a proteogenomic approach, novel peptides are identified by searching MS/MS spectra against customized protein sequence databases containing predicted novel protein sequences and sequence variants; such databases are generated using genomic and transcriptomic sequence information. Proteogenomics therefore not only provides protein-level validation of gene expression and gene model refinement but also enables the improvement of protein sequence databases (Fig. 2) .
In recent years, the pace of proteogenomic research has greatly accelerated. Substantial improvements in the depth and throughput of mass spectrometry-based proteomic technologies have been achieved. The development of proteomic data repositories (Box 2) has also improved access to published large-scale proteomic data sets. Additionally, advances in sequencing technologies have dramatically changed the genome-characterization landscape. As a result, proteogenomics is being increasingly applied to organisms with previously unsequenced or partially sequenced genomes-organisms for which proteomic and DNA sequencing data can now be acquired in a rapid and cost-effective manner. For many organisms, especially human and model organisms, a tremendous amount of the transcrip- Proteins are digested into peptides, separated using liquid chromatography (LC) coupled online to a mass spectrometer and then analyzed by the mass spectrometer, which generates tandem mass spectra. (b) Peptides are most commonly identified using a sequence database (DB) search approach. Traditionally, experimental MS/MS spectra are matched with theoretical spectra predicted for each peptide contained in a protein sequence database. Sequence tag-assisted database searching starts with extraction of short tags followed by database searching, in which the list of candidate peptides is restricted to only those peptides that contain one of the extracted sequence tags, thereby allowing for mutations in the sequences of candidate database peptides. Peptide sequence can also be extracted directly from the spectrum using de novo sequencing (extracted sequences can then be searched in a protein sequence database to find the exact or a homologous peptide).
NATURE METHODS | VOL.11 NO.11 | NOVEMBER 2014 | 1115 REVIEw npg coding region and the neighboring intron region (exon extensions), peptides spanning unannotated (alternative) splice junctions and out-of-frame peptides. Novel peptides may also provide evidence of protein expression for chimeric transcripts, transcripts thought to be noncoding RNAs, gene fusions and RNA-editing events, although such events are expected to be rare in proteomic data sets.
Generation of customized protein sequence databases
The key step in proteogenomics is peptide identification by matching acquired MS/MS spectra against a customized protein sequence database. Here I describe in more detail different strategies and data sources used to generate such databases. The final database is typically created by combining predicted protein sequences with an equal number of 'decoy' sequences for subsequent FDR analysis and then appending known sequences (i.e., a reference protein sequence database) and the corresponding set of decoys. A note of caution: proteogenomics users need to balance database comprehensiveness with the increased search time and elevated FDR that come with searching larger databases (see below). The optimal choice depends on the goals of the experiments; more specifically, on the types of novel peptides that the study seeks to identify.
Six-frame translation of the genome. Predicted protein sequences can be generated using six-frame translation of the genomic sequence [21] [22] [23] [24] [25] using, for example, the "getorf " program in the EMBOSS (European Molecular Biology Open Software Suite) package. Limitations of this strategy are the extremely large size of the resulting database 23 , a 70-fold increase compared to the ~45 Mb of the corresponding Ensembl reference protein sequence database. Several computational strategies can be used to eliminate less likely sequences, including selection of the most likely frame on the basis of homology to known coding sequences, using predictions of the coding potential and possibly excluding translated sequences that are shorter than a certain minimum length (for example, 30 amino acids) 26 .
Ab initio gene prediction. Instead of direct six-frame translation of the genome, protein-coding regions can be identified with the help of ab initio gene-prediction algorithms: for example, Augustus or GeneID, as was done in refs. 25, 27, 28 . Empirical information such as cDNA sequence data can be used as part of the gene-prediction process as well 25 (for a review of gene-prediction algorithms, see ref. 29) . One advantage of using predicted exons is the knowledge of the reading frame. Identification of exon-exon junction peptides (including novel junction peptides) is also possible by generating theoretical junction peptides connecting all predicted exon sequences within a gene 27 . The resulting protein sequence databases can still be very large, for example, a tenfold increase (selecting the gene-prediction parameters allowing for maximum sensitivity) over the size of a typical reference protein sequence database 27 . With the knowledge of the genomic coordinates of predicted exons, the computational efficiency of the peptide identification process can be improved by creating a compact representation of all possible splice junctions using the exon splice graph approach 25, 28, 30 . This process merges transcripts with shared sequence, so that every predicted exon appears only once in the graph.
Expressed sequence tag (EST) data. Protein sequences can be predicted using six-frame translation of EST data, which provides experimental evidence of transcription, including information about intron-exon structure and splicing. Although EST data are already used as part of gene-annotation pipelines, they can be reanalyzed independently to predict a larger set of protein sequences 28, [31] [32] [33] . Compared to the ab initio gene-prediction strategy, ESTs provide a more direct way to generate peptide sequence candidates, including novel junction peptides and SAVs. The drawback is again a substantial increase in the size of the resulting database (~300 times the size of the reference protein sequence databases for human 32 ) due to the unknown translation frame and the number of accumulated ESTs (for example, almost 9 million sequences in the US National Center for Biotechnology Information (NCBI) human dbEST database at this time). For more efficient computational analysis, ESTs can be processed to generate a compressed protein sequence database, effectively eliminating most of the redundant sequences 32 . Several additional filtering steps can be applied, such as requiring that the ESTs map to the vicinity of a known gene, keeping only translated peptide sequence of a certain minimum length, and requiring that all peptide sequences are confirmed by multiple ESTs (to minimize sequencing errors). ESTs can also be clustered to generate a set of putative exons and introns, and a compact protein sequence database can then be generated using the splice graph approach 28 .
Annotated RNA transcripts. Protein sequences can be generated using three-frame translation of annotated RNA transcripts from, for example, Ensembl (GENCODE) or RefSeq, i.e., going beyond the annotated coding sequence and translation frame. This allows identification of alternative translation initiation sites (TISs) and out-offrame peptides but without the sequence-space explosion typical of other strategies. For example, translation of the human GENCODE v.7 annotated transcripts (mRNA of 84,408 annotated protein sequences) results in an ~200-megabyte database size 23 , i.e., only a 4.5-fold increase over the size of the corresponding reference protein sequence database. Customized protein sequence databases generated this way can include translations of RNA transcripts annotated as pseudogenes or lncRNAs 34 . Given the explicit knowledge of the exon-intron structure, mRNA transcript annotations can be used to generate theoretical peptides corresponding to all combinatorial exon-exon junction possibilities.
RNA-seq data. Customized protein sequence databases can be generated on the basis of information from RNA-seq data. Transcript reconstruction using RNA-seq data starts with read mapping, i.e., alignment of short reads to the reference genome using, for example, a popular Bowtie-TopHat combination or ultrafast aligners such as STAR (reviewed in ref. 35 ). The splice junctions reported by the aligner (keeping junctions supported by a certain minimum number of reads only) can be extended into the exon regions on both sides of the junction and then translated to generate a comprehensive database of splice junction peptide sequences 11, 13 . Full transcriptome reconstruction (assembly) can be achieved using, for example, Cufflinks (for a review of transcriptome assemblers, see ref. 36) . A genome-guided assembly approach is recommended for organisms with referenced genomes, whereas a genome-independent (de novo) strategy can be applied to any organism but requires more advanced expertise and bioinformatics infrastructure (evaluated for proteogenomic applications in ref. 37) . Reconstructed transcripts are aligned using the basic local alignment search tool (BLAST) or An increasing number of proteomic data sets are now available in public repositories such as PRIDE (http://www.ebi.ac.uk/pride/archive/) and PeptideAtlas (http://www. peptideatlas.org/), the two major repositories within the larger ProteomeXchange consortium (http://proteomexchange.org/). Other existing data repositories include ProteomicsDB (https://www.proteomicsdb.org/); MassIVE (http://proteomics.ucsd. edu/ProteoSAFe/), which includes data rescued after the collapse of the previously commonly used Tranche data repository; and Chorus (http://chorusproject.org/). CPTAC data are released through a dedicated data portal (https://cptac-data-portal. georgetown.edu/cptacPublic/). PeptideAtlas and the Global Proteome Machine (GPMdb; http://thegpm.org/) provide results of a uniform reanalysis of raw data submitted to proteomic data repositories, including data generated as part of the C-HPP project (http://www.peptideatlas.org/hupo/c-hpp/). Although GPMdb itself does not store raw data, it serves as a useful resource for identifying relevant data sets available in the public domain.
BOX 2 MASS SPECTROMETRY DATA REPOSITORIES
NATURE METHODS | VOL.11 NO.11 | NOVEMBER 2014 | 1117 REVIEw npg compared using genomic coordinates to the reference transcripts to remove redundant sequence. Additionally, they are filtered using a certain minimum level of abundance (estimated using mapped read counts). Remaining transcripts are translated, again optionally keeping predicted protein sequences of a certain minimum length 15 . Ribosome-profiling data can be used in essentially the same way 12 . The process can be automated using several recently described bioinformatics tools. Using the Galaxy-P system, users can convert input RNA-seq data into three types of protein sequence databases suitable for proteogenomic analysis: databases containing novel SAVs, databases containing novel splice junction sequences, and reduced databases containing only proteins corresponding to transcripts above a certain minimum level of expression 38 . customProDB 39 performs similar tasks and also incorporates variant sequences extracted from public databases (see below). Protein sequence databases can also be generated from large-scale RNAseq data aggregated from multiple studies using the splice graph approach 25, 40 .
Variant sequences. Protein sequences in a reference database can be extended to include protein-changing variants (SAVs, but also single-amino-acid deletions and insertions) cataloged in various public resources. For each variant, the reference sequence is modified accordingly, and a larger sequence region covering the variant site is added as an independent entry to the customized database 41 . SAVs can be downloaded from the NCBI dbSNP database and supplemented with known disease mutations from the Online Mendelian Inheritance in Man database and the Protein Mutant Database 41 . For building customized databases from RNA-seq data, customProDB 35 can combine SAVs and short insertion and deletions (identified from RNA-seq) with known SAVs extracted from the dbSNP database. RNA-editing events can be detected via the bioinformatic comparison of RNA and DNA data from the same samples using publicly available tools 42 .
Other specialized databases. Reference RNA transcripts can also be supplemented with predicted transcripts from more specialized databases. These include the ECgene database, which applies less stringent procedures for construction of gene models and transcript assembly to encompass a larger number of alternative splicing events (see, for example, ref. 43); the Pseudogene.org database (http:// pseudogene.org/), the noncoding RNA sequence database NONCODE 44 (used in ref. 17) or the Broad Institute of MIT and Harvard's collection of large intergenic noncoding RNAs and transcripts of unknown coding potential 45 (used in ref. 18 ). The ChiTaRS database of chimeric RNAs transcripts 46 represents readthrough events and gene fusions identified in the literature and using computational analysis of ESTs and RNA-seq data (used in ref. 47 ).
Peptide identification using customized protein databases
In proteogenomics, and in proteomics in general, successful peptide identification depends on the completeness of the protein sequence database, the sensitivity and specificity (error rates) associated with a particular peptide identification strategy, the computational time and resources necessary for processing the data, and the ability to interpret the results in a biological context. Many of these issues I have reviewed previously 3 ; below, I focus on these aspects from a proteogenomics perspective.
Effect of database size. The ability to identify the correct peptide sequence that generated an experimental MS/MS spectrum using the database search approach depends on multiple factors. First, it requires that the peptide sequence is present in the searched protein sequence database. However, the more candidates there are to be scored against an experimental MS/MS spectrum, the higher the likelihood that the best-scoring match to the spectrum is incorrect, and also the more difficult it becomes to distinguish between true and false identifications 3 . As a result, although searching MS/MS spectra against large proteogenomic databases may result in a (relatively small) number of novel peptide identifications, the total number of identified peptides may drop substantially compared to that from conventional reference sequence database searching 26, 48 (for example, by 30% or more when using six-frame genome translation 26 ). Searching larger databases also increases the computational time and requires additional modifications to common data analysis workflows: for example, splitting the searched database into multiple chunks 24 . Thus, a key consideration in proteogenomics is the selection of the optimal strategy for generating the customized 
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ner, the results of the initial search are used to refine the customized database used in subsequent searches. For example, the most likely frame of translation can be inferred with the help of high-scoring peptides identified in the initial search 26 . Similarly, the search for alternative TISs can be restricted to genomic regions containing a proteincoding gene identified by high-confidence known peptides; a novel alternative splice junction can be considered only if both corresponding exons are supported by highscoring exon-mapping peptides.
Estimating identification confidence.
Accurate statistical assessment of the identification confidence for different classes of peptides is a crucial step in proteogenomics. As with proteomics in general, redundant peptide-spectrum matches (PSMs) should be collapsed and represented by the highest-scoring PSM to prevent accumulation of error rates when going from PSM level to unique-peptide-ion level 3 .
Identifications of the same peptide sequence from multiple peptide ions (for example, doubly and triply charged ions) or in multiple forms (for example, unmodified and oxidized methionine forms) should also be collapsed (as a conservation approach) or treated probabilistically 53 . In multistage strategies, in which the searched protein sequence database is constructed on the basis of previous search results, it is imperative to generate and include in the customized database an appropriate number of decoy sequences at each stage of the analysis 3 . In addition to the estimation of global error rates (FDR), it is important to estimate the confidence in each individual event (for example, posterior probability of true peptide identification; for a discussion on this and related statistical concepts in mass spectrometry-based proteomics, see ref.
3). When a particular protein or, in proteogenomics, a particular 'event' (such as a novel coding region or a splice junction) is identified from multiple peptide ions and/ or multiple unique peptides, the posterior probabilities of the supporting identifications can in principle be combined to calculate the probability score for that event 53, 54 . Such models, however, have not yet been tested on proteogenomic data.
Class-specific analysis and FDR estimation. When estimating the posterior probabilities for individual peptides and the specific events that they define (for example, novel coding regions), it is necessary to take into consideration the difference in the likelihood of identifying different classes of peptides 11, 50 . The direct analogy in conventional proteomic data analysis is performing enzyme-unconstrained MS/MS database searches (i.e., allowing nontryptic peptides) when analyzing data generated from trypsin-digested protein samples. Just as nontryptic peptides are required to have stronger supporting evidence (for example, database search scores) than tryptic pepsequence database, i.e., finding the right balance between the completeness of the database and its size.
Strategies for improving the sensitivity of peptide identification.
Strategies known in proteomics to increase the number of identified peptides include application of multiple database search tools to the same data set 49 and post-database search rescoring of peptide identifications via combining multiple sources of information using machine learning techniques 3 . One complementary strategy to reduce search space is to fractionate peptides before LC-MS/MS analysis on the basis of a certain physicochemical or sequence property of the peptides. For example, using isoelectric focusing, MS/ MS spectra from a particular isoelectric focusing fraction can be scored against only candidate peptides having a predicted isoelectric point expected for that fraction (isoelectric point-restricted database search) 50 .
Improved sensitivity of peptide identification in proteogenomics can also be achieved using a multistage data analysis strategy. This type of analysis can start by searching a reference protein sequence database to interpret a majority of MS/MS spectra and then proceed to searching larger databases to interpret the MS/MS spectra that remain unidentified after the initial search 33 
Figure 4 | Statistical assessment of peptide identifications in proteogenomics. MS/MS spectra (Spec)
are searched against a customized protein sequence database (DB) that includes target sequences for the organism of interest, i.e., a reference protein database and predicted protein sequences (containing novel peptides). In addition, two 'decoy' databases (for example, containing reversed sequences) of the same sizes as the target reference and predicted databases are appended to the target databases. The best database peptide match for each spectrum is selected for further analysis. Peptide identifications are classified as known or novel (for a decoy peptide, the class-known or novel-is determined by the class of the corresponding target sequence from which the decoy was generated). When simple database search score-based filtering is used, the numbers of target and decoy peptide identifications passing a certain score threshold are counted and used to estimate the FDR corresponding to that threshold. FDR analysis should be done separately for known and novel peptides (class-specific FDR) because of differences in the number of known and novel sequences in the searched customized sequence database and because of the lower likelihood of correctly identifying a novel peptide. For more advanced methods based on computing posterior peptide probabilities, both the database search scores and the peptide class (known or novel) should be taken into consideration.
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REVIEw npg tides to obtain the same level of confidence 3 , novel peptides identified using proteogenomic approaches should be required to have stronger evidence than known peptides. Further, among the novel peptides, peptides identifying very rare events (for example, intergenic peptides suggesting the presence of novel protein-coding loci) should require stronger supporting evidence than those identifying more common events (for example, alternative TISs for known protein-coding regions). Thus, when using the target-decoy strategy for FDR estimation, the analysis should be done separately for each class of peptides (at least known vs. novel, but ideally also separately for different categories of novel peptides) to compute the class-specific FDR (Fig. 4) . Similarly, for more advanced approaches involving computation of posterior probabilities using, for example, the model-based approach of PeptideProphet 3 , the underlying statistical models should explicitly incorporate the peptide class. Note that in many published proteogenomic studies, including two recent largescale human studies 17, 18 , the same database search-score cutoffs were applied across all categories of peptides, known or novel. Thus, it is likely that the error rates among the novel peptides reported in these studies are substantially higher than acknowledged.
False peptide identifications of nonrandom nature. Incorrect peptide identifications result from two different sources: random high-scoring matches of MS/MS spectra to unrelated sequences and matches to peptides homologous to the true peptides. Regardless of how the decoy database is generated (for example, reversing or randomizing target protein sequences), false identifications of the second kind are likely to be underestimated 3 , especially when large customized protein sequence databases are used. A common scenario is false identification of a novel peptide from an MS/MS spectrum acquired on a chemically modified, highly abundant peptide ion with a mass shift introduced by the chemical modification equaling the mass difference between the novel and the unmodified known peptide 33, 55 . As a general guideline, it is advisable to compare-for example, using BLAST-the sequence of each identified novel peptide against the sequences of all peptides in the reference database to detect and eliminate (or at least clearly mark) all identifications of novel peptides with a high degree of homology to a known sequence. When it is important to keep such peptides (for example, when specifically searching for SAVs), it is necessary to check that the observed mass shift between the novel peptide and the closest homolog(s) in the reference database does not match the mass of one of the common chemical or post-translational modifications (for example, oxidation, deamidation, carbamylation, acetylation, etc.) 25, 33, 41, 50, 51, 55 . The sample-specific list of the most common chemical modifications for a particular biological sample can be established using 'blind' modification search tools 56 . Furthermore, isoleucine/leucine substitutions cannot be distinguished using mass spectrometry, and thus such peptides should not be included in the list of identified peptide variants.
Levels of data summarization and inference of novel events. In proteomics, results are typically presented as a list of identified proteins (protein-level summary) or genes (gene-level summary), along with a list of identified unique peptides, with FDR estimated at these levels. In proteogenomics, these levels of data summarization are not sufficient, and results should explicitly include the types of events that a particular proteogenomic study seeks to identify. For example, "novel coding region" or "TIS" identification events should be provided as separate lists in addition to the protein and/or gene levels of data summarization and the supporting unique peptide evidence. The same peptide sequence may arise from multiple different genomic locations (such as from gene paralogs or from a protein-coding gene and a pseudogene). Such 'shared' peptides ('multimapped' in the language used in the transcriptome literature) do not provide unambiguous evidence of protein expression at a particular locus 4 . Furthermore, a novel peptide mapping to single location in the genome could also have multiple (ambiguous) interpretations: for example, as supporting one event type for one transcript of a gene and another event type for another transcript of the same gene (for example, out-of-frame peptide and intronic/UTR peptide). Thus, the principle of parsimony in creating the summary lists described previously for proteomics 4 , i.e., presenting multiple protein sequence database entries identified by the same peptides as indistinguishable groups, should be extended and applied to proteogenomic studies as well.
Defining novel peptides.
The results of a proteogenomic analysis, and in particular the peptides reported as novel, depend on the reference database selected in that study, and even the specific version of that database. As discussed above, multiple reference protein sequence databases exist for many organisms, and these databases vary in terms of their completeness and annotation quality. Furthermore, all major reference databases are constantly updated, with new entries added and some removed with each new version. Therefore, in proteogenomic studies, peptides identified using customized protein sequence databases should be mapped to all major reference databases available for the organism under investigation and to common sample contaminants, and protein annotations available for the closest matches in those databases should be reported as part of the final output.
PROTEOGENOMIC APPLICATIONS
The feasibility of various proteogenomic applications has been discussed and demonstrated in multiple studies in human and in many model organisms, including in Plasmodium falciparum 57 , Caenorhabditis elegans 58 , Drosophila melanogaster 22 , Arabidopsis thaliana 21, 30 and Anopheles gambiae 59 (Supplementary Table 1) . Only a few of these studies, however, exhibited attributes of a directed, comprehensive proteogenomics project-a consistent and coordinated effort on the part of both genomics and proteomics groups, with a functioning feedback mechanism in which the sequences of the identified peptides are passed to (and used by) the genome annotators. The members of the Encyclopedia of DNA Elements (ENCODE) project and its subproject GENCODE made attempts to include proteomic data in their work on the improved annotation of the mouse 27 and human 23 genomes. The limited extent of these and other early proteogenomic studies could be attributed in part to a lack of sufficient amount of proteomic data, low sensitivity of the previous generations of proteomic technologies and lack of understanding of proteomic data by the genomic community. As a result, most proteogenomic studies in human and model organisms, including recent large-scale studies 17, 18 , focused on a less ambitious but nevertheless important task of providing proteinlevel 'validation' , i.e., confirmation of the protein-level expression of putative gene models or sequence variants predicted from the genome sequence and often supported by transcriptional evidence. Recent improvements in proteomic technologies, coupled with 1120 | VOL.11 NO.11 | NOVEMBER 2014 | NATURE METHODS REVIEw npg identification of peptides mapping to 5ʹ UTRs or to downstream inframe AUG codons, a large number of proteins or protein isoforms with different (compared to the reference annotation) N-terminal extensions or truncations 67 . It has been noted that in human and mouse proteomes, up to 20% of all identified protein N termini point to alternative TISs, incorrect assignments of the translation start codon, the use of translation initiation at near-cognate start codons or alternative splicing events resulting in a different N-terminal protein sequence 67 .
Alternative splicing
Alternative splicing is a major source of cell-specific and tissuespecific protein variation in higher eukaryotes 20, 68 . Most early proteogenomic studies were based on the analysis of EST data, with MS/ MS spectra searched either directly against six-frame translation of the EST sequences 32 or against customized databases of alternative splice transcripts: for example, the ECgene database constructed using EST data with the help of gene-modeling algorithms 69 . In recent years, the analysis of alternative splicing using proteomic data has been increasingly reliant on the availability of RNA-seq transcriptome data for generation of customized databases from six-frame translation of reconstructed transcripts 14, 37 and predicted splice junctions 11, 13 . A recent proteogenomic analysis of the HeLa cell line using a custom splice junction database created from the samplespecific RNA-seq data resulted in the detection of 57 novel splice junction peptides (out of 24,834 novel transcript junctions identified in RNA-seq data), representing an array of different splicing events, including skipped exons and alternative donor and acceptor sites 13 .
Sequence variants
Identification of sequence variants using genomic technologies, including disease-associated variants, is a long-standing area of research. As with alternative splicing, because of the overwhelming number of variants detected in the genome and transcriptome data, understanding which of those variants are functional is a challenging task 70 . Detection of these variants at the protein level provides an opportunity to reduce the set of candidates for subsequent investigation of their functional role or clinical relevance. The ability to search for all possible amino acid mutations using MS/MS data has been implemented in several commonly used database search tools (for example, Mascot and X!Tandem), but such an approach is computationally inefficient (sequence tag-based database search strategies, also shown in Fig. 1 , allow minor speed improvement 5, 55 ). Even more important than search speed is that any strategy that considers all possible amino acid mutations quickly loses sensitivity owing to a very large increase in the search space, and the error rates become a serious concern. Sequence variants can be identified in a more targeted way by searching against translated ESTs 32 , but the more commonly used approach involves building customized databases of protein sequences explicitly incorporating known variant peptides. In one such recent example, 81 distinct variant peptides were identified in proteomic data from three colon cancer cell lines, and 204 variants in three lung cancer tissues, by searching MS/MS spectra against a custom CanProVar (human cancer proteome variation) database 41 . As with other applications discussed above, when the same samples are profiled using both RNA-seq and proteomics, the custom sequence database for variant peptide identification can be generated from the RNA-seq data 14, 37, 71, 72 . Using this strategy and one of the most comprehensive proteomic data sets to date, researchers wide availability of high-throughput DNA and transcriptome sequencing data, have led to a resurgence of proteogenomic studies. In human and mouse, the focus of many such studies has shifted toward detection of abnormal protein variants (for example, SAVs) across cohorts of cancer tissue samples 60 , exemplified by the recent publication from the Cancer Proteomic Tumor Analysis Consortium (CPTAC) 19 . Several common proteogenomic applications, and the type of new information they seek to obtain, are discussed in more detail below.
Novel protein-coding regions
The possibility of using MS/MS proteomic data for discovery of novel protein-coding regions, and refinement of gene boundaries for previously annotated ones, has been discussed since the early days of proteomics 31, 61 . This is most commonly achieved by searching MS/MS spectra against customized databases generated using direct six-frame genome translation, three-frame translation of protein-coding sequences predicted using ab initio gene-prediction algorithms, or six-frame translation of the transcripts reconstructed from the EST or RNA-seq data (three-frame if strand-specific RNAseq). The efforts to discover novel protein-coding regions are likely to be most fruitful for less studied, nonmodel organisms 25, 30, 62 the organisms that have not benefitted from extensive genomeannotation efforts. Even for well-annotated higher eukaryotes, recent studies report a substantial numbers of novel identifications. For example, a deep proteome-profiling study (to the depth of 13,078 human and 10,637 mouse proteins) reported the identification of 98 and 52 previously undiscovered protein-coding loci in human and mouse, respectively, using the six-frame genometranslation approach 50 .
Short open reading frames and translation initiation sites
The computational prediction of short open reading frames (sORFs), and frames that use non-AUG initiation codons, is particularly difficult 62 . It has been suggested that sORFs may account for an additional 10% of the number of protein-coding elements in eukaryote genomes 63 . These sORFs may be located within a genomic region of an annotated transcript (for example, in the 5ʹ UTR located upstream of a known open reading frame or resulting from a frameshift within the coding sequence of the ORF) or within unannotated transcripts or intergenic regions thought to be lacking protein-coding capacity. With the advent of ribosomeprofiling methods, strong experimental evidence for the existence of protein-coding sORFs and non-AUG TISs have emerged (reviewed in ref. 62) . Although ribosome profiling and conventional RNA-seq demonstrate the protein-coding potential of these sORFs, proteogenomics provides additional evidence for the production of a stable protein product encoded by them 12, 64, 65 . The search for peptides confirming sORFs and novel TISs is likely to be most fruitful with one or several additional sample-preparation steps. The likelihood of identifying a peptide from an sORF greatly increases with fractionation of protein samples before LC-MS/MS analysis to enrich for low-molecular weight proteins 65 . Detection of novel TISs generally requires conclusive identification of N-terminal peptides that can be enriched before mass spectrometric analysis using protein N terminus labeling approaches (N-terminal proteomics 66 ).
In a recent study, N-terminal proteomic data were analyzed using a customized protein sequence database created using publicly available ribosome-profiling data. The study revealed, via the fairly complete proteome profiles with less effort. The benefits of performing simultaneous proteogenomic analysis of data from multiple related species, termed comparative proteogenomics, have also been discussed 80, 81 .
Metaproteomics
Proteogenomics has the potential to make substantial contributions in the analysis of community samples such as microbial communities studied in environmental genomics and microbiomics 82, 83 . This area of research, referred to as metaproteomics or community proteogenomics 79, 84 , is concerned with untangling the interplay among many different organisms contained within the analyzed communities. At the same time, metaproteomics presents great challenges. The organisms that constitute such communities are typically poorly annotated (and thus their known reference proteomes are far from complete); moreover, the presence of multiple highly homologous organisms makes conclusive protein identification and quantification difficult 85 . Several recent studies highlighted the importance of properly generating customized protein sequences databases for metaproteomics [85] [86] [87] using DNA sequencing data obtained for single microorganisms, along with protein sequences parsed from RefSeq and UniProtKB at different taxonomic levels. The large size of the customized protein sequence databases typical of metaproteomic studies requires substantial computational resources, lowers the sensitivity of peptide identification and raises the rate of misidentifications. Furthermore, because the ability to quantitatively compare the abundances of proteins from different organisms within the community samples is important, it is necessary to apply label-free protein quantification strategies designed to accurately deal with a large number of shared peptides mapping to multiple homologous proteins in different organisms 88 .
CONCLUDING REMARKS
Early efforts in proteogenomics were hampered by technical challenges resulting from an overall low sensitivity of proteomic technology. The last several years, however, have witnessed great improvements in mass spectrometry instrumentation, including new instrument types, alternative fragmentation mechanisms and advanced data-acquisition strategies 1,2 . These developments, coupled with improvements in protein separation and enrichment methods for proteomic applications, have resulted in a substantial increase in the depth of protein detection, approaching that of global transcriptome-profiling studies 1 . Significant advances have also been achieved in top-down proteomics-a technology that offers complementary information useful for proteogenomic characterization 89 . A major challenge in proteogenomics has been the lack of a sufficient amount of proteomic data in the public domain necessary to make a substantial contribution to genome-annotation efforts, in part owing to the 'data hoarding' mentality prevalent in the proteomics community in the early days. There has been a clear shift toward more open data sharing in proteomics, further strengthened by new requirements from funding agencies 90 . As a result, an increasing number of proteomic data sets are now available in public repositories 91 .
Although the depth of RNA-seq data is still greater than that of proteomic data, transcriptome data contain elements not expected to comprise mature proteins (for example, a large number of nonfunctional transcripts) 92 . Ribosome-profiling data provide evidence of translational activity and thus can be used to identify novel transcripts that are more likely to be protein coding. Still, these data detected 38 and 88 nonsynonymous variants at the peptide level in two different strains of rat 14 . Furthermore, more than 1,000 variant peptides were reported in a recent comprehensive study using proteomic data from a large cohort of cancer tissue samples from The Cancer Genome Atlas (TCGA) initiative 19 . Although this number is impressive, it is necessary to keep in mind the difficulty with estimating FDR for variant peptides as discussed above.
Other sources of genome variation
Multiple other sources of genome variation of high biological significance potentially result in novel or variant protein-coding transcripts. These include RNA editing, which occurs during posttranslation processing and whose role and biological significance has yet to be fully understood. The extent to which these events are present in the transcriptome is being debated (reviewed in ref. 73 ), but it is likely to be less than what was initially thought 74 . Proteogenomics may provide valuable protein-level evidence for some of these putative RNA-editing events 14 . It may also provide evidence of protein expression for novel gene fusions and chimeric transcripts 47 and transcripts annotated as pseudogenes 27 . The function and coding potential of transcripts annotated as lncRNAs is another very active area of research 75 . If expressed, these proteins are likely to be at a very low level, meaning that these events have a very low likelihood of being detected in a typical proteomic data set 76 . Thus, extra caution should always be applied with respect to FDR estimation when looking for evidence of such peptides in proteomic data.
Nonmodel organisms
Although humans and model organisms have received extensive attention regarding their genome annotation, this is clearly not the case for organisms with unsequenced or partially sequenced genomes, for which consistent gene-annotation efforts are lacking. Thus, proteogenomics can be very impactful for nonmodel organisms. Until recently, the genome and cDNA sequencing data for nonmodel organisms were scarce. As a result, the reference protein sequence databases for these organisms were incomplete and poorly annotated. This gave rise to homology-based proteomic data analysis strategies-a combination of de novo peptide sequencing ( Fig. 1) and sequence-similarity searching against protein databases of homologous organisms 77, 78 .
More recently, with the advent of new sequencing technologies, it has become possible to rapidly and cost-effectively determine the genome sequence of any species of interest. Although these data can then be analyzed using computational gene-annotation pipelines, automated approaches make a relatively high number of annotation errors. Importantly, in the absence of expert manual curationespecially for organisms for which related sequences are not available, and thus homology-guided annotation is not possible (for example, many microorganisms)-proteomic data are often the only source of experimental evidence confirming the protein expression of computationally predicted gene models. The significance of proteogenomics for nonmodel organisms has been illustrated using microbial organisms and plants. These efforts have been recently reviewed in ref. 79 (for an extended list of published proteogenomic efforts for a variety of organisms, see Supplementary Table 1) . Prokaryotes are particularly amenable to proteogenomic analysis owing to their smaller genomes, their single-cell organization (i.e., intraindividual and interindividual homogeneity) and the smaller dynamic range of their proteomes, which allows for generation of initiative. These initiatives not only provide rich proteomic data sets for proteogenomic analysis but also present an opportunity for the development of advanced data integration and modeling strategies across the entire spectrum of 'omics data. There is a need for making proteomic data in general, and the results of proteogenomic analyses in particular, more accessible and useful to a broader scientific community. A good start would be the development of a computational infrastructure for querying specific novel peptides of interest to a particular laboratory across a large collection of publicly available proteomic data, including C-HPP and CPTAC data, to obtain and visualize protein-level evidence of their expression.
Looking at proteogenomics in a broader context, questions remain as to what fraction of novel alternative splice forms are translated into stable functional proteins versus those that are prone to nonsense-mediated decay or protein degradation immediately following translation. Further analysis can help identify the differences between confirmed (at the protein level) and unconfirmed splice forms in terms of their secondary structure and sequence properties 96, 97 . Recent studies also suggest that SAVs could affect protein stability 14 , possibly explaining the lower-than-expected rate of detection of such variants in proteomic data 41 . Furthermore, somatic variants have been found to have lower protein abundance that that of germline variants 19 . These and other recent studies [98] [99] [100] involving quantitative analysis of transcripts and protein expression data as well as integration with DNA variation provide valuable insights into how the proteome is regulated using genetic effects. In summary, there is every indication that the field of proteogenomics will remain an active area of research. do not provide direct evidence of expression of a stable, functional protein. Thus, despite the clear success of RNA-seq and related technologies in uncovering the previously uncharacterized diversity of the genome, proteomic data play a critical role in identifying functional transcripts among the many novel transcripts nominated by genomic and transcriptomic technologies. Joint analyses using multi-omics data should be particularly informative when done in close collaboration between the genomics and proteomics groups, with biological experiments carefully designed to generate paired genomic-proteomic data sets.
Incorrect peptide and protein identifications have been a longstanding problem in proteomics 3 . In the early days, many data sets with very high FDR were published, prompting calls to establish robust data analysis and publication guidelines 93 . Proteogenomics presents additional challenges that are not yet fully acknowledged. I have highlighted the most significant sources of false discoveries in proteogenomics, including application of the same filtering thresholds to both known and novel peptides, incorrect identification of novel peptides highly homologous to known sequences, and making unsupported conclusions based on shared peptides. Future efforts should focus on establishing data analysis guidelines for proteogenomic studies, extending some general guidelines I present here (Box 3).
Proteogenomics is playing a central role in two ongoing large-scale initiatives. The community-driven Chromosome-Centric Human Proteome Project (C-HPP) has a broad goal of characterizing the parts list of the human proteome 94 , whereas the CPTAC 95 project, funded by the US National Institutes of Health, aims to uncover the molecular basis of cancer via proteomics characterization of common cancer specimens obtained though the TCGA Here I suggest some guidelines for reporting novel peptides identified in a proteogenomic analysis.
• Customized protein sequence databases used to identify novel peptides should be made available upon publication.
• Peptides identified using customized protein databases should be queried against all major reference databases available for the organism of interest (for example, RefSeq, UniProtKB and Ensembl) and also mapped to common sample contaminants. For each peptide reported as novel, the closest reference peptide sequence(s) should be listed, along with the accession numbers of the corresponding proteins.
• The FDR estimation procedure applied to novel peptides, and how it is different than that applied to known peptides, should be clearly described. To the degree possible, different categories of novel peptides should be analyzed separately.
• When novel peptides homologous to a reference sequence are reported, the efforts taken to eliminate the most likely sources of false positives (for example, common posttranslational and chemical modifications, errors in mass measurements, etc.) should be described.
• Peptides mapping to multiple genome locations should be clearly marked. The same peptides should not be used as evidence for multiple different proteins or protein forms.
